Alyson Moadel Discusses Partner-Related Prostate Cancer Side Effects

Planning for adverse effects early on helps patients prepare for what lies ahead, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Patients with advanced RCC who were treated with nivolumab plus cabozantinib had a median PFS of 16.4 months compared with 8.3 months from sunitinib alone.

In this episode of "The Vitals," Heather Jackson, PhD, FNP-BC, NEA-BC, FAANP, shares her experience helping a patient reduce their opioid use through acupuncture treatments.

MyCareGorithm was met with high approval from patients, companions, and physicians, with all 3 groups reporting they’d recommend the tool to other patients.

Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone.